Literature DB >> 20137772

Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene.

Varda Levy-Litan1, Eli Hershkovitz, Luba Avizov, Neta Leventhal, Dani Bercovich, Vered Chalifa-Caspi, Esther Manor, Sophia Buriakovsky, Yair Hadad, James Goding, Ruti Parvari.   

Abstract

Human disorders of phosphate (Pi) handling and hypophosphatemic rickets have been shown to result from mutations in PHEX, FGF23, and DMP1, presenting as X-linked recessive, autosomal-dominant, and autosomal-recessive patterns, respectively. We present the identification of an inactivating mutation in the ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) gene causing autosomal-recessive hypophosphatemic rickets (ARHR) with phosphaturia by positional cloning. ENPP1 generates inorganic pyrophosphate (PPi), an essential physiologic inhibitor of calcification, and previously described inactivating mutations in this gene were shown to cause aberrant ectopic calcification disorders, whereas no aberrant calcifications were present in our patients. Our surprising result suggests a different pathway involved in the generation of ARHR and possible additional functions for ENPP1. Copyright (c) 2010 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20137772      PMCID: PMC2820183          DOI: 10.1016/j.ajhg.2010.01.010

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  23 in total

1.  Enzymic hydrolysis of phosphonate esters.

Authors:  S J Kelly; L G Butler
Journal:  Biochem Biophys Res Commun       Date:  1975-09-02       Impact factor: 3.575

Review 2.  Lessons from studying monogenic disease for common disease.

Authors:  Leena Peltonen; Markus Perola; Jussi Naukkarinen; Aarno Palotie
Journal:  Hum Mol Genet       Date:  2006-04-15       Impact factor: 6.150

3.  Bone talk.

Authors:  Susan C Schiavi
Journal:  Nat Genet       Date:  2006-11       Impact factor: 38.330

4.  Tandem repeats finder: a program to analyze DNA sequences.

Authors:  G Benson
Journal:  Nucleic Acids Res       Date:  1999-01-15       Impact factor: 16.971

5.  Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.

Authors:  Yuji Yamazaki; Ryo Okazaki; Minako Shibata; Yukihiro Hasegawa; Kohei Satoh; Toshihiro Tajima; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Takeyoshi Yamashita; Seiji Fukumoto
Journal:  J Clin Endocrinol Metab       Date:  2002-11       Impact factor: 5.958

Review 6.  Inorganic pyrophosphate generation and disposition in pathophysiology.

Authors:  R A Terkeltaub
Journal:  Am J Physiol Cell Physiol       Date:  2001-07       Impact factor: 4.249

Review 7.  Deficiencies of physiologic calcification inhibitors and low-grade inflammation in arterial calcification: lessons for cartilage calcification.

Authors:  Frank Rutsch; Robert Terkeltaub
Journal:  Joint Bone Spine       Date:  2005-03       Impact factor: 4.929

8.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

9.  Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification.

Authors:  Frank Rutsch; Nico Ruf; Sucheta Vaingankar; Mohammad R Toliat; Anita Suk; Wolfgang Höhne; Galen Schauer; Mandy Lehmann; Tony Roscioli; Dirk Schnabel; Jörg T Epplen; Alex Knisely; Andrea Superti-Furga; James McGill; Marco Filippone; Alan R Sinaiko; Hillary Vallance; Bernd Hinrichs; Wendy Smith; Merry Ferre; Robert Terkeltaub; Peter Nürnberg
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

10.  Epistatic effects contribute to variation in BMD in Fischer 344 x Lewis F2 rats.

Authors:  Daniel L Koller; Lixiang Liu; Imranul Alam; Qiwei Sun; Michael J Econs; Tatiana Foroud; Charles H Turner
Journal:  J Bone Miner Res       Date:  2008-01       Impact factor: 6.741

View more
  119 in total

Review 1.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 2.  Hereditary disorders of renal phosphate wasting.

Authors:  Amir S Alizadeh Naderi; Robert F Reilly
Journal:  Nat Rev Nephrol       Date:  2010-10-05       Impact factor: 28.314

Review 3.  The expanding family of hypophosphatemic syndromes.

Authors:  Thomas O Carpenter
Journal:  J Bone Miner Metab       Date:  2011-12-14       Impact factor: 2.626

Review 4.  Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism.

Authors:  L Darryl Quarles
Journal:  Nat Rev Endocrinol       Date:  2012-01-17       Impact factor: 43.330

5.  It ANKH necessarily so.

Authors:  Michael T Collins; Manfred Boehm
Journal:  J Clin Endocrinol Metab       Date:  2011-01       Impact factor: 5.958

Review 6.  FGF23 and Phosphate Wasting Disorders.

Authors:  Xianglan Huang; Yan Jiang; Weibo Xia
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

Review 7.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

8.  Primary ciliary dyskinesia caused by homozygous mutation in DNAL1, encoding dynein light chain 1.

Authors:  Masha Mazor; Soliman Alkrinawi; Vered Chalifa-Caspi; Esther Manor; Val C Sheffield; Micha Aviram; Ruti Parvari
Journal:  Am J Hum Genet       Date:  2011-04-14       Impact factor: 11.025

Review 9.  The Causes of Hypo- and Hyperphosphatemia in Humans.

Authors:  Eugénie Koumakis; Catherine Cormier; Christian Roux; Karine Briot
Journal:  Calcif Tissue Int       Date:  2020-04-13       Impact factor: 4.333

10.  Inherited disorders of calcium and phosphate metabolism.

Authors:  Jyothsna Gattineni
Journal:  Curr Opin Pediatr       Date:  2014-04       Impact factor: 2.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.